Acute Assessment of the Aria CV System in Patients With WHO Groups 2 and 3 Pulmonary Hypertension

Inclusion Criteria for WHO Group 2

1. 18 years or older

2. Symptomatic WHO Functional Class (FC) III

3. Based on preexisting echocardiography within the past 6 months, evidence of right heart dysfunction: RV ejection fraction (RVEF) < 45% by visual estimate, and at least one of the following:

4. Tricuspid Annulus Plane Systolic Excursion (TAPSE) ≤16 mm

5. RV Fractional area change <35%

6. RVs' velocity < 10 cm/s

7. RV free wall strain <18%

8. RVEF < 35% by visual estimate

9. MPA diameter > 32mm and length >70 mm as determined by preexisting fluoroscopy, echocardiography, computerized tomography, or magnetic resonance imaging within the past 6 months.

10. Elevated pulmonary arterial pressure based on preexisting resting RHC within the past 6 months: Mean PAP (mPAP) > 30 mmHg

11. Intra-procedural confirmation of elevated pulmonary arterial pressure based on resting RHC: mPAP > 30 mmHg

12. Patient is willing and able to provide informed consent.

13. Previous diagnosis of left heart dysfunction.

14. Intra-procedural confirmation of WHO Group 2 diagnosis based on resting RHC:

15. PAWP: >15 and ≤30 mmHg, and

16. Combined post- and pre-capillary pulmonary hypertension (CpcPH), defined as PVR > 3 WU

Exclusion Criteria for WHO Group 2

1. Anatomy not suitable for RHC

2. Anatomy not suitable for placement of Aria CV Acute Device:

3. Contraindication to 16 Fr femoral vein access

4. Body habitus that would preclude safe placement of any components of Aria CV Acute Device

5. Any previous tricuspid valvular surgery, percutaneous valve repair, or presence of prosthetic cardiac device such as pacemaker or defibrillator leads, or vena cava filter that in the opinion of the investigator may interfere with investigational device placement or performance

6. Uncontrolled atrial fibrillation

7. Sustained tachyarrhythmia (heart rate >110/min) at time of index procedure

8. Right heart valve regurgitation:

9. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation

10. Severe (Grade 4) tricuspid valve regurgitation

11. Patient with any of the following medical history or comorbidities:

12. History of unprovoked Pulmonary Embolism or CTEPH

13. Currently on dialysis

14. Current or recent (<6 months prior to planned index procedure) endocarditis

15. Clinically significant patent foramen ovale or other inter-atrial or inter-ventricular shunt

16. Current active systemic infection requiring antibiotic therapy

17. As determined by the physician the subject is medically unstable and/or represents an unreasonable procedural risk.

18. Hypersensitivity or contraindication to

19. Required medications (e.g. contrast agents, heparin) which cannot be adequately managed, or

20. Materials in investigational device including polyurethane, silicone, nickel, and titanium

21. Pregnant or lactating woman

22. Currently participating in other investigational drug or device trials that may interfere with the outcome of this study

23. Diagnosis of WHO Groups 1, 3, 4 or 5 PH

24. Previous diagnosis of idiopathic hypertrophic subaortic stenosis (IHSS, also known as hypertrophic obstructive cardiomyopathy-HOCM)

25. Untreated aortic or mitral stenosis

Inclusion Criteria for WHO Group 3

1. 18 years or older

2. Symptomatic WHO Functional Class (FC) III

3. Based on preexisting echocardiography within the past 6 months, evidence of right heart dysfunction: RV ejection fraction (RVEF) < 45% by visual estimate, and at least one of the following:

4. Tricuspid Annulus Plane Systolic Excursion (TAPSE) ≤16 mm

5. RV Fractional area change <35%

6. RVs' velocity < 10 cm/s

7. RV free wall strain <18%

8. RVEF < 35% by visual estimate

9. MPA diameter > 32mm and length >70 mm as determined by preexisting fluoroscopy, echocardiography, computerized tomography, or magnetic resonance imaging within the past 6 months

10. Elevated pulmonary arterial pressure based on preexisting resting RHC within the past 6 months: Mean PAP (mPAP) > 30 mmHg

11. Intra-procedural confirmation of elevated pulmonary arterial pressure based on resting RHC: mPAP > 30 mmHg

12. Patient is willing and able to provide informed consent

13. Previous diagnosis of chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis

14. Intra-procedural confirmation of WHO Group 3 diagnosis based on resting RHC:

15. PAWP≤ 15 mmHg, and

16. PVR > 4 WU

Exclusion Criteria for WHO Group 3

1. Anatomy not suitable for RHC

2. Anatomy not suitable for placement of Aria CV Acute Device:

3. Contraindication to 16 Fr femoral vein access

4. Body habitus that would preclude safe placement of any components of Aria CV Acute device

5. Any previous tricuspid valvular surgery, percutaneous valve repair, or presence of prosthetic cardiac device such as pacemaker or defibrillator leads, or vena cava filter that in the opinion of the investigator may interfere with investigational device placement or performance

6. Uncontrolled atrial fibrillation

7. Sustained tachyarrhythmia (heart rate >110/min) at time of index procedure

8. Right heart valve regurgitation:

9. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation

10. Severe (Grade 4) tricuspid valve regurgitation

11. Patient with any of the following medical history or comorbidities:

12. History of unprovoked Pulmonary Embolism or CTEPH

13. Currently on dialysis

14. Current or recent (<6 months prior to planned index procedure) endocarditis

15. Clinically significant shunt such as patent foramen ovale, inter-atrial or inter-ventricular shunt, or other.

16. Current active systemic infection requiring antibiotic therapy

17. As determined by the physician the subject is medically unstable and/or represents an unreasonable procedural risk.

18. Hypersensitivity or contraindication to

19. Required medications (e.g. contrast agents, warfarin, heparin) which cannot be adequately managed, or

20. Materials in investigational device including polyurethane, silicone, nickel, and titanium.

21. Pregnant or lactating woman

22. Currently participating in other investigational drug or device trials that may interfere with the outcome of this study

23. Diagnosis of WHO Groups 1, 2, 4 or 5 PH